Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia

Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia Soheil Meshinchi, Robert J. Arceci Oncologist 2007; 12: 341-355 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in pediatric oncology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (required). Learning Objectives After completing this course, the reader should be able to: Identify specific favorable and high-risk factors in pediatric AML. Discuss the rationale and indications for the use of stem cell transplantation in pediatric AML. Describe new technologies and emerging molecular prognostic markers in pediatric AML. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Apr. 3, 2007 Most Recent Review: Apr. 3, 2007* Most Recent Update: Apr. 3, 2007 Date Credit Expires: Apr. 3, 2009 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

• Take this course